GTCR-backed Corza Health completed the acquisition of TachoSil from Takeda for $414m.

GTCR-backed Corza Health, a developer of healthcare technology, completed the acquisition of TachoSil, a surgical patch to deliver bleeding control, from Takeda Pharmaceutical, a global, research and development-driven pharmaceutical company, for $414m. “This announcement continues Takeda’s strong momentum toward optimizing our portfolio for growth by delivering highly-innovative medicines and transformative care in our chosen business areas, as well as meeting our leverage targets. As we continue to streamline and simplify our portfolio, Takeda is confident that we have found the right partner in Corza Health as the next home for TachoSil. Corza Health’s expertise in healthcare, commitment to patients, customers and employees, and resources in partnership with GTCR make it well-positioned to ensure continued patient access to TachoSil and to invest in the product over the long term for their benefit,” Costa Saroukos, Takeda Chief Financial Officer.